--- title: "Anika Therapeutics (ANIK) stock: news and investor profile" url: "https://aibio.space/companies/anika-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Anika Therapeutics, Inc. (NASDAQ: ANIK), United States. The directory classifies it as Biopharma / pharmaceuticals." --- ANIK Anika Therapeutics, Inc. NASDAQ · United States # Anika Therapeutics (ANIK) news Debt Financing · 2026-07-10 ## [Anika Therapeutics amends $50.0 million Bank of America revolving credit line](https://aibio.space/news/anika-therapeutics-amends-50-0-million-bank-america-revolving-credit/) Anika Therapeutics signed a fifth amendment to its Bank of America revolving credit line, now maturing July 10, 2031. The filing names no amount drawn, and the line carries a first-priority lien on most of the company's assets. ## Latest Anika Therapeutics news 1. 2025-03-11 Mergers [Anika Therapeutics sells Parcus Medical to Medacta for $4,500,000 in cash](https://aibio.space/news/anika-therapeutics-sells-parcus-medical-medacta-4-500-000-cash/) Anika completed the sale of its former subsidiary Parcus Medical to Medacta Americas Manufacturing on March 7, 2025 for $4,500,000 in cash at closing, still subject to post-closing adjustments. The 2023 annual report shows a $62.2 million impairment on the Parcus and Arthrosurface intangibles. 2. 2025-03-11 Mergers [Anika Therapeutics completes sale of Parcus Medical to Medacta Group](https://aibio.space/news/anika-therapeutics-completes-sale-parcus-medical-medacta-group/) The deal closed on March 7, 2025 for an undisclosed amount, paid in cash at closing. Anika will now focus on hyaluronic acid pain products and regenerative solutions. ## Anika Therapeutics at a glance - **Ticker**: ANIK - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $38.4 million ### Related companies - [Apollomics](https://aibio.space/companies/apollomics/) NASDAQ: APLM - [Polaryx Therapeutics](https://aibio.space/companies/polaryx-therapeutics/) NASDAQ: PLYX - [Tectonic Therapeutic](https://aibio.space/companies/tectonic-therapeutic/) NASDAQ: TECX - [Dyadic International](https://aibio.space/companies/dyadic-international/) NASDAQ: DYAI - [Serina Therapeutics](https://aibio.space/companies/serina-therapeutics/) AMEX: SER - [Lantheus Holdings](https://aibio.space/companies/lantheus/) NASDAQ: LNTH - [Bone Biologics](https://aibio.space/companies/bone-biologics/) NASDAQ: BBLG - [Cardiff Oncology](https://aibio.space/companies/cardiff-oncology/) NASDAQ: CRDF ### Also on NASDAQ - [CAMP4 Therapeutics](https://aibio.space/companies/camp4-therapeutics/) CAMP - [Lantheus Holdings](https://aibio.space/companies/lantheus/) LNTH - [Faeth Therapeutics](https://aibio.space/companies/faeth-therapeutics/) FTH - [ProMIS Neurosciences](https://aibio.space/companies/promis-neurosciences/) PMN - [Novavax](https://aibio.space/companies/novavax/) NVAX - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) PVLA ## What Anika Therapeutics does Anika Therapeutics, Inc., founded in 1992, is a company that uses proprietary hyaluronic acid, or HA, technology to develop products for osteoarthritis pain management and regenerative solutions in early intervention orthopedics. Its OA Pain Management portfolio includes Monovisc and Orthovisc, single- and multi-injection HA viscosupplements indicated for pain relief from OA, and Cingal, a non-opioid, single-injection product that combines cross-linked HA with a fast-acting steroid. Cingal is CE marked and has been sold outside the United States directly in over 50 countries, but it is not currently approved for commercial use in the United States. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. The Regenerative Solutions portfolio includes the Integrity Implant System, an HA-based scaffold for rotator cuff and other tendon repairs. Anika submitted a premarket approval application for Hyalofast on October 31, 2025, and received an FDA letter in January 2026 identifying deficiencies that the company is addressing. The company sold Arthrosurface and Parcus Medical to focus on these two portfolios. | Product or program | What it is | Stage | |---|---|---| | Monovisc | Single-injection HA viscosupplement for osteoarthritis pain, labeled for the knee in the U.S. | Marketed | | Orthovisc | Multi-injection HA viscosupplement for osteoarthritis pain | Marketed | | Cingal | Non-opioid single-injection HA with a fast-acting steroid for OA pain | CE marked; not currently approved in the United States | | Hyalofast | Regenerative Solutions product for which a U.S. PMA was submitted | PMA submitted October 31, 2025; FDA deficiency letter January 2026 | | Integrity Implant System | HA-based scaffold for rotator cuff and other tendon repairs | | Summarised from the company's [10-K filed Mar 3, 2026](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm). ## Anika Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$112.8 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | [$119.9 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | | Research and development | [$25.8 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | [$25.5 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | | Net income (loss) | [-$10.9 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | [-$56.4 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | | Cash from operations | [$11.2 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | [$5.4 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | | Cash and equivalents | [$57.5 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326005012/) | [$55.6 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | | Short-term investments | [$23.7 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326002852/) | [$23.6 million](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $38.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Anika Therapeutics What is the ticker symbol of Anika Therapeutics? Anika Therapeutics, Inc. trades under the ticker ANIK on NASDAQ. Where is Anika Therapeutics listed? Anika Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Anika Therapeutics? The SEC Central Index Key (CIK) for Anika Therapeutics, Inc. is 898437. Its filings are on SEC EDGAR. How many shares does Anika Therapeutics have outstanding? 13,382,966 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-07-29. Which country or territory is Anika Therapeutics listed under? Our directory records Anika Therapeutics, Inc. under United States. What does Anika Therapeutics do? Our directory classifies Anika Therapeutics, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Anika Therapeutics? The ISIN recorded for Anika Therapeutics, Inc. is US0352551081. Does aibio.space cover Anika Therapeutics? aibio.space lists Anika Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Anika Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Anika Therapeutics develop? Anika Therapeutics, Inc., founded in 1992, is a company that uses proprietary hyaluronic acid, or HA, technology to develop products for osteoarthritis pain management and regenerative solutions in early intervention orthopedics. Its OA Pain Management portfolio includes Monovisc and Orthovisc, single- and multi-injection HA viscosupplements indicated for pain relief from OA, and Cingal, a non-opioid, single-injection product that combines cross-linked HA with a fast-acting steroid. What is Monovisc from Anika Therapeutics? Monovisc: Single-injection HA viscosupplement for osteoarthritis pain, labeled for the knee in the U.S. Stage: Marketed. What is Orthovisc from Anika Therapeutics? Orthovisc: Multi-injection HA viscosupplement for osteoarthritis pain Stage: Marketed. What was Anika Therapeutics's revenue last year? $112.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Anika Therapeutics profitable? Anika Therapeutics, Inc. reported a net loss of $10.9 million for the fiscal year ended Dec 31, 2025, and generated $11.2 million of cash from operations, per its annual report to the SEC. How much does Anika Therapeutics spend on research and development? $25.8 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Anika Therapeutics Members talk about Anika Therapeutics (ANIK). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Anika Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-03-11 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/exh_991.htm) 2. 2024-10-31 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/898437/000117184324005922/exh_991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ANIK on TradingView](https://www.tradingview.com/symbols/NASDAQ-ANIK/). ## SEC filings and registration - **SEC name**: Anika Therapeutics, Inc. - **CIK**: 898437 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: ANIK (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: 32 WIGGINS AVENUE, BEDFORD, MA, 01730 - **Phone**: (781) 457-9000 - **Shares outstanding**: 13,382,966 as of 2026-07-24 (10-Q filed 2026-07-29) - **Former names**: ANIKA THERAPEUTICS INC; ANIKA RESEARCH INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/898437/000117184326005012/anik20260630_10q.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/898437/000117184326004977/f8k_072926.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/898437/000117184326004635/f8k_071426.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/898437/000117184326004253/f8k_062326.htm) filed 2026-06-23 - [10-Q](https://www.sec.gov/Archives/edgar/data/898437/000117184326002852/anik20260331_10q.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/f8k_042926.htm) filed 2026-04-29 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/898437/000114036126017488/ny20067128x1_def14a.htm) filed 2026-04-28 - [10-K](https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm) filed 2026-03-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000898437), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Anika Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ANIK, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Anika Therapeutics, Inc. - **Ticker**: ANIK - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US0352551081 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ANIK/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/anika-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Anika Therapeutics (ANIK) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/anika-therapeutics/